T1	intervention 33 65	oral adjuvant clodronate therapy
T2	total-participants 406 429	Two hundred sixty-eight
T3	eligibility 430 491	pre- and postmenopausal, node-positive breast cancer patients
T4	control 569 583	control groups
T7	outcome 1115 1134	spinal osteoporosis
T8	iv-bin-abs 1136 1141	three
T9	intervention-participants 1145 1147	41
T10	cv-bin-abs 1177 1179	11
T11	control-participants 1183 1185	48
T12	total-participants 913 924	Eighty-nine
T13	outcome 1251 1267	hip osteoporosis
T14	iv-bin-abs 1269 1274	seven
T15	intervention-participants 1278 1280	41
T16	cv-bin-abs 1310 1315	seven
T17	control-participants 1319 1321	48
T18	outcome 1365 1396	osteoporosis-free survival rate
T19	iv-bin-percent 1401 1406	92.7%
T20	cv-bin-percent 1436 1441	77.0%
T21	outcome 1505 1534	frequency of hip osteoporosis
T22	iv-bin-percent 1536 1541	85.4%
T23	cv-bin-percent 1544 1549	82.9%
T5	condition 98 110	osteoporosis
T6	outcome 1570 1573	BMD
T25	outcome 1771 1809	incidence of lumbar spine osteoporosis
